Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

(2012) Calvin J. Cohen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

(2011) Laurence Rimsky et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Suppression of HIV Replication by Antiretroviral Therapy Reduces TIM-3 Expression on HIV-Specific CD8+ T Cells

(2010) Afework Kassu et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design

(2010) Eric B. Lansdon et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

Etravirine, a Next‐Generation Nonnucleoside Reverse‐Transcriptase Inhbitor

(2009) Leonard B. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor

(2009) Lucy Garvey et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS